Suppr超能文献

局部递送组织因子抗体可减少早期白细胞浸润,但未能限制实验性静脉移植物中的内膜增生。

Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts.

作者信息

Annex B H, Davies M G, Fulton G J, Huynh T T, Channon K M, Ezekowitz M D, Hagen P O

机构信息

Department of Surgery, Atherosclerosis and Vascular Biology Research Laboratory, Duke University Medical Center/Durham VA Medical Center, Durham, North Carolina, 27710, USA.

出版信息

J Surg Res. 1998 Dec;80(2):164-70. doi: 10.1006/jsre.1998.5438.

Abstract

BACKGROUND

Tissue Factor-mediated thrombin generation involves the generation of VIIa and Xa and has been implicated in the pathogenesis of intimal hyperplasia. In experimental vein grafts, Tissue Factor protein is increased over the first 3 days and colocalized with CD18-positive leukocytes; this increase in Tissue Factor precedes the development of intimal hyperplasia. This study further evaluates the potential role of Tissue Factor in vein graft intimal hyperplasia by directly inhibiting Tissue Factor protein.

METHODS

New Zealand white rabbits underwent interpositional bypass grafting of the common carotid artery using the external jugular vein. Perioperatively, murine anti-rabbit Tissue Factor antibody (109 microg/ml gel, 12,500x IC50 of Tissue Factor activity) was applied to the adventitial surface of the graft, using a pluronic gel (30% soln.). Tissue Factor antibody treated vein grafts were compared to control and empty gel-treated vein grafts. Vein grafts were examined at 3 days to assess CD18-positive leukocyte infiltration and the presence of residual antibody by Western blotting. At 28 days, intimal and medial dimensions were quantified using videomorphometry.

RESULTS

At day 3, there was marked reduction in CD18-positive leukocytes in the Tissue Factor antibody versus control vein grafts (6.3 +/- 4.7 vs 20.8 +/- 7.4 per 200x field, P < 0.05). At 28 days, intimal hyperplasia was similar for the control (70 +/- 4 microm, mean +/- SEM), gel (73 +/- 4 microm), and Tissue Factor antibody (75 +/- 4 microm) vein grafts. However, medial thickness (76 +/- 4 microm;, P < 0.05) was significantly increased compared to the gel treated vein graft (61 +/- 5 microm).

CONCLUSION

Local delivery of pharmacologic doses of an anti-rabbit Tissue Factor antibody decreased CD18-positive leukocyte infiltration but failed to limit intimal hyperplasia in experimental vein grafts. The results suggest that inhibition of Tissue Factor protein modulates polymorphonuclear leukocyte-endothelial interactions but not in the subsequent development of intimal hyperplasia. It implies that the relationship between the extrinsic coagulation cascade and intimal hyperplasia in vein grafts is complex.

摘要

背景

组织因子介导的凝血酶生成涉及VIIa和Xa的生成,并与内膜增生的发病机制有关。在实验性静脉移植物中,组织因子蛋白在最初3天内增加,并与CD18阳性白细胞共定位;组织因子的这种增加先于内膜增生的发展。本研究通过直接抑制组织因子蛋白,进一步评估组织因子在静脉移植物内膜增生中的潜在作用。

方法

新西兰白兔采用颈外静脉进行颈总动脉间置旁路移植术。围手术期,使用普朗尼克凝胶(30%溶液)将鼠抗兔组织因子抗体(109微克/毫升凝胶,组织因子活性的12500倍IC50)应用于移植物的外膜表面。将组织因子抗体处理的静脉移植物与对照和空凝胶处理的静脉移植物进行比较。在3天时检查静脉移植物,通过蛋白质印迹法评估CD18阳性白细胞浸润和残留抗体的存在。在28天时,使用视频形态测量法定量内膜和中膜尺寸。

结果

在第3天,组织因子抗体处理的静脉移植物中CD18阳性白细胞明显少于对照静脉移植物(每200倍视野6.3±4.7个 vs 20.8±7.4个,P<0.05)。在28天时,对照(70±4微米,平均值±标准误)、凝胶(73±4微米)和组织因子抗体(75±4微米)静脉移植物的内膜增生相似。然而,与凝胶处理的静脉移植物(61±5微米)相比,中膜厚度(76±4微米;P<0.05)显著增加。

结论

局部递送药理剂量的抗兔组织因子抗体可减少CD18阳性白细胞浸润,但未能限制实验性静脉移植物中的内膜增生。结果表明,抑制组织因子蛋白可调节多形核白细胞与内皮细胞的相互作用,但不能抑制内膜增生的后续发展。这意味着静脉移植物中外源性凝血级联与内膜增生之间的关系很复杂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验